No Data
Prothena (NASDAQ:PRTA) Spikes 17% This Week, Taking Five-year Gains to 144%
When you buy a stock there is always a possibility that it could drop 100%. But when you pick a company that is really flourishing, you can make more than 100%. Long term Prothena Corporation plc (
Prothena Price Target Maintained With a $28.00/Share by RBC Capital
Prothena Price Target Maintained With a $28.00/Share by RBC Capital
Prothena Corp Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/26/2024 38.82% RBC Capital $28 → $28 Reiterates Sector Perform → Sector Perform 05/09/2024 311.5% JMP S
RBC Capital Maintains Prothena(PRTA.US) With Hold Rating, Maintains Target Price $28
RBC Capital analyst Brian Abrahams maintains $Prothena(PRTA.US)$ with a hold rating, and maintains the target price at $28.According to TipRanks data, the analyst has a success rate of 49.2% and a tot
Here's Why We're Not Too Worried About Prothena's (NASDAQ:PRTA) Cash Burn Situation
Pinning Down Prothena Corporation Plc's (NASDAQ:PRTA) P/S Is Difficult Right Now
It's not a stretch to say that Prothena Corporation plc's (NASDAQ:PRTA) price-to-sales (or "P/S") ratio of 12.3x right now seems quite "middle-of-the-road" for companies in the Biotechs industry in t